Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pulmatrix

7.79
+0.38505.20%
Volume:14.17K
Turnover:106.81K
Market Cap:28.43M
PE:-2.94
High:7.88
Open:7.16
Low:7.16
Close:7.40
Loading ...

Company Profile

Company Name:
Pulmatrix
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
22
Office Location:
36 Crosby Drive,Suite 100,Bedford,Massachusetts,United States
Zip Code:
01730
Fax:
- -
Introduction:
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Directors

Name
Position
Michael J. Higgins
Chairman of the Board,Director
Teofilo Raad
Director,Chief Executive Officer
Anand Varadan
Director
Christopher Cabell
Director
Richard Batycky
Director
Todd Bazemore
Director

Shareholders

Name
Position
Teofilo Raad
Director,Chief Executive Officer
Peter Ludlum
Interim Chief Financial Officer
Margaret Wasilewski
Chief Medical Officer
Michelle S. Siegert
Vice President, Finance